Skip to content Skip to footer
Subscribe Now
NEWS

InnoCare and KeyMed Together Partner with Prolium Bioscience to Develop ICP-B02

Shots:InnoCare & KeyMed together have signed an exclusive license agreement with Prolium to develop & commercialize ICP-B02 (CM355) Prolium gains exclusive rights to develop, manufacture & commercialize ICP-B02 globally (non-oncology) and in ex-Asia regions (oncology) while InnoCare & KeyMed will get a total of ~$520M (upfront & near-term payments), minority equity stake in…
January 21, 2025

Read more

VIEWPOINTS_Michael Moran1_Julie Blaedel2_2024
VIEWPOINTS

Julie Blaedel from Genmab and Michael Moran from AbbVie Discuss the Conditional EC Approval of TEPKINLY in a Stimulating Conversation with PharmaShots

Shots:   Diffuse large B-cell lymphoma remains the most common type of non-Hodgkin lymphoma. With limited therapeutic options for patients whose disease gets relapsed or refractory, AbbVie and Genmab’s TEPKINLY is one-of-a-kind monotherapy for adult patients with relapsed or refractory DLBCL  Post EC’s conditional approval, Julie Blaedel & Michael Moran engage in an enlightening conversation with…
January 10, 2024

Read more